Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for J Frontier Co., Ltd. (2934:JPX), powered by AI.
J Frontier Co., Ltd. is currently trading at ¥1,467. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for J Frontier Co., Ltd. on Alpha Lenz.
J Frontier Co., Ltd.'s P/E ratio is 84.2.
“J Frontier Co., Ltd. trades at a P/E of 84.2 (premium valuation) with modest ROE of 6.9%. 3Y revenue CAGR of 21.9% highlights clear growth momentum.”
Ask for details →J Frontier Co., Ltd. is a Japanese company primarily engaged in the development and operation of e-commerce services. Its main focus is on healthcare and beauty products, catering to the growing online marketplace in Japan and potentially beyond. J Frontier Co., Ltd. operates platforms that facilitate the purchase of pharmaceuticals and healthcare products, aiming to enhance the consumer experience by offering a wide selection of goods in a convenient online format. This positions the company well within the health and wellness sector, which is seeing increasing demand due to global trends in healthy living and aging populations. J Frontier also uses strategic partnerships to expand its product base and enhance its market reach. In the financial market, J Frontier Co., Ltd. represents an opportunity to engage with the expanding digital retail landscape, while also underlining the rising significance of e-commerce in meeting consumer needs. The company’s focus on leveraging technology to meet the evolving demands of consumers underscores its role as a forward-looking participant in the online healthcare and beauty industry.
“J Frontier Co., Ltd. trades at a P/E of 84.2 (premium valuation) with modest ROE of 6.9%. 3Y revenue CAGR of 21.9% highlights clear growth momentum.”
Ask for details →J Frontier Co., Ltd. (ticker: 2934) is a company listed on JPX in the Healthcare sector (Pharmaceutical Retailers). It has approximately 202 employees. Market cap is $7.4B.
The current price is 1,467 with a P/E ratio of 84.21x and P/B of 5.24x.
ROE is 6.88% and operating margin is 1.37%. Annual revenue is $21.5B.